latanoprost and Low-Tension-Glaucoma

This was the first exploratory randomized controlled study to compare the efficacy and safety of a preserved tafluprost/timolol fixed combination (TAF/TIM) with a preserved latanoprost/timolol fixed combination (LAT/TIM).. This prospective, randomized, open-label study was conducted in Japanese patients with primary open-angle glaucoma, including normal-tension glaucoma or ocular hypertension. Following a 4-week LAT/TIM run-in period, eligible patients entered a 12-week treatment period, during which they received either LAT/TIM or TAF/TIM. The efficacy endpoint was the change in intraocular pressure (IOP) from baseline to week 12 and the safety endpoints included the changes from baseline to week 12 in superficial punctate keratopathy (SPK) score, tear breakup time (TBUT), and hyperemia score, as well as adverse events (AEs). At week 6, ocular symptoms were evaluated using a questionnaire.. In total, 131 patients provided informed consent. Of these, 115 completed the run-in period and were assigned to receive TAF/TIM (n = 60) or LAT/TIM (n = 55). At week 12, there were no significant differences between the TAF/TIM and LAT/TIM groups in the change from baseline in trough IOP and IOP at 4-6 h after instillation. There were no significant differences between the two groups in the change from baseline to week 12 in SPK score, TBUT, and hyperemia score. However, only in the TAF/TIM group, the total SPK score and the inferior cornea SPK score were significantly lower at week 12 compared with baseline. Eye irritation and eye pain were significantly decreased in the TAF/TIM group compared with the LAT/TIM group. Two treatment-related AEs were reported in the TAF/TIM group (3.3%) and none in the LAT/TIM group, while no serious AEs were reported in either group.. TAF/TIM is as effective as LAT/TIM in terms of IOP-reducing effect, with fewer ocular symptoms. TAF/TIM was associated with a significant improvement in SPK scores.. UMIN Clinical Trials Registry Identifier, UMIN000023862.. Santen Pharmaceutical Co., Ltd., Osaka, Japan.

Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Japan; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Prostaglandins F; Prostaglandins F, Synthetic; Timolol; Tonometry, Ocular; Young Adult

To assess the noninferiority of a dorzolamide-timolol fixed combination (DTFC) versus latanoprost in terms of intraocular pressure (IOP) and to compare blood pressure (BP), ocular perfusion pressure (OPP) and diastolic ocular perfusion pressure (DOPP) between the latanoprost and DTFC groups in patients with normal-tension glaucoma (NTG).. Prospective, interventional, randomized, single-blinded, crossover design study. Patients with newly diagnosed NTG that had not been treated with a glaucoma medication in the most recent 2 months were recruited. In total, 44 patients with NTG were randomly allocated to one of two groups. Patients in group A were treated with DTFC, lubricant, and latanoprost for 4 weeks each, whereas patients in group B were treated with latanoprost, lubricant, and DTFC for 4 weeks each. Patients were examined on day 1 (without medication), week 4 (under medication), week 8 (without medication), and week 12 (under medication). At weeks 4 and 12, diurnal IOP, systolic and diastolic BP, and OPP were measured at 8:00 AM, 10:00 AM, 12:00 PM, 4:00 PM, and 8:00 PM.. Baseline demographic characteristics showed no difference in terms of age, sex, central corneal thickness, spherical equivalent, or stage of glaucoma between the groups. The between-group difference was -0.19 ± 0.18 mmHg (mean ± SE, upper bound of one-sided 95% CI, 0.12). Diurnal IOP showed no difference between the groups with an average IOP reduction of 13.1% using latanoprost and 12.3% using DTFC. Diurnal systolic and diastolic BP were lower in the DTFC group than the latanoprost group; however, the difference between the groups was not statistically significant. Diurnal OPP and DOPP also showed no statistically significant difference between the groups.. IOP lowering efficacy of DTFC was noninferior to that of latanoprost in newly diagnosed NTG patients. There was no difference in BP, OPP, or DOPP between the latanoprost and DTFC groups. This prospective, randomized, single-blinded, crossover study demonstrated the noninferiority of DTFC versus latanoprost in terms of IOP in patients with NTG.. ClinicalTrials.gov NCT01175902.

Topics: Blood Pressure; Circadian Rhythm; Cross-Over Studies; Demography; Diastole; Drug Combinations; Female; Heart Rate; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Perfusion; Prostaglandins F, Synthetic; Sulfonamides; Systole; Thiophenes; Timolol

A prospective study was performed to compare the ocular pulse amplitude (OPA)-lowering effects of tafluprost and latanoprost, used in the treatment of glaucoma, using dynamic contour tonometry.. The study population consisted of patients with normal-tension glaucoma (NTG) (n = 27) or primary open-angle glaucoma (POAG) (n = 14) treated with tafluprost and latanoprost. All patients were newly diagnosed with NTG and POAG and had undergone no previous treatment. Intraocular pressure (IOP) was measured by Goldmann applanation tonometry (GAT), OPA was measured by dynamic contour tonometry, and corrected OPA (cOPA) was calculated before and after 1 week, 1-3 months of treatment.. Initial IOP and OPA were 17.12 ± 3.75, 2.30 ± 0.56 mmHg and 17.53 ± 2.87, 2.65 ± 0.94 mmHg in the tafluprost and latanoprost groups, respectively. After 3 months of treatment, IOP and OPA were 13.00 ± 2.04 mmHg (24.1%) and 1.51 ± 0.30 mmHg (34.3%), respectively, in the tafluprost group. These values were 15.40 ± 2.32 mmHg (12.2%) and 2.08 ± 0.83 mmHg (21.5%), respectively, in the latanoprost group. Therefore, tafluprost significantly reduced IOP (P = 0.01), but OPA-lowering effects did not differ significantly between the 2 groups (P = 0.17). However, the cOPA-lowering effect of tafluprost (1.27 mmHg, 55.2%) was significantly greater than that of latanoprost (0.84 mmHg, 31.7%) after 3 months of treatment (P < 0.001).. Tafluprost and latanoprost, used to treat glaucoma, have marked OPA-lowering effects as well as IOP-lowering effects. Moreover, tafluprost has a greater effect than latanoprost. Therefore, it can be used for patients in need of IOP reduction and at risk of glaucoma progression.

Topics: Adult; Aged; Antihypertensive Agents; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Prospective Studies; Prostaglandins F; Prostaglandins F, Synthetic; Tonometry, Ocular; Treatment Outcome

To compare the ocular hypotensive effect of travoprost plus timolol (TTFC) and latanoprost plus timolol fixed combinations (LTFC) in patients with normal-tension glaucoma (NTG).. A two-sequence 12-week, multicenter, prospective, randomized, single-blinded, crossover clinical trial examined 59 NTG patients. If both eyes were eligible, only one eye (chosen at random) was used for analytical purposes. After a 12-week run-in period with dorzolamide plus timolol fixed combination (DTFC), patients were randomized into one of the two crossover sequences of treatment for 12 weeks with TTFC or LTFC and were subsequently crossed over to the alternative treatment for a further 12 weeks. The primary endpoint was reduction in IOP after 12 weeks of each treatment sequence. The effect of treatment on IOP was assessed using a linear mixed model.. The mean baseline IOP was 14.8 ± 3.3 mm Hg (95% confidence interval [CI], 14.1-15.3 mm Hg) for treatment with DTFC. The TTFC treatment period showed consistently lower mean IOP compared with LTFC treatment period at all measurement time points. Mean reduction in IOP at 12 weeks was significantly greater in the TTFC group than in the LTFC group (-2.4 ± 2.3 mm Hg vs. -1.1 ± 2.3 mm Hg; P = 0.021). No interaction between the drug and treatment sequence was detected. The effects of intraocular lens implantation and measurement time were also not significant. The tolerability profiles of both treatments were similar.. The additional reduction in IOP was greater with TTFC than with LTFC, and their tolerability profiles were similar. (http://www.umin.ac.jp/ctr/ number, UMIN 000005974.).

Topics: Aged; Antihypertensive Agents; Cloprostenol; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Prospective Studies; Prostaglandins F, Synthetic; Single-Blind Method; Timolol; Travoprost

The aim of this study was to evaluate the efficacy and safety of bimatoprost in Japanese patients with normal-tension glaucoma (NTG) who showed insufficient response to latanoprost.. A prospective, nonrandomized study was conducted in patients with NTG, with ≤20% intraocular pressure (IOP) decrease from pretreatment baseline with latanoprost monotherapy who had been switched to bimatoprost. The IOP was measured at 4, 8, and 12 weeks after the switch to bimatoprost. In 12 weeks after the switch to bimatoprost, efficacy and safety were evaluated.. Postswitch to bimatoprost, IOP was significantly reduced at every visit. Bimatoprost produced significantly greater mean% IOP reduction rate from pretreatment than that of latanoprost at week 12 (P<0.01). There was a significant correlation between% IOP reduction of bimatoprost and that of latanoprost (Pearson r(2)=0.374; P=0.007). No significant difference was observed in the mean scores of conjunctival hyperemia and corneal epithelial disorder between bimatoprost-treated eyes and latanoprost-treated eyes.. Significant additional IOP lowering was achieved by switching to bimatoprost in Japanese patients with NTG with insufficient response to latanoprost. Bimatoprost treatment was safe and well tolerated.

Topics: Administration, Ophthalmic; Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Bimatoprost; Cloprostenol; Epithelium, Corneal; Female; Follow-Up Studies; Humans; Hyperemia; Intraocular Pressure; Japan; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Prospective Studies; Prostaglandins F, Synthetic; Treatment Outcome

To compare the efficacy and tolerance of three prostaglandin analogues, bimatoprost, latanoprost and travoprost in patients with previously untreated open-angle glaucoma and ocular hypertension.. Prospective randomized single (investigator) masked comparative clinical trial at the Taunton and Somerset NHS Hospital, Taunton, UK. Newly diagnosed, treatment naïve glaucoma/ocular hypertension patients were recruited. Patients were randomized into three groups to receive one of the three prostaglandin analogues. Intraocular pressure (IOP) was measured before starting treatment and after 2 and 6 months of treatment. The IOP reduction and the tolerance profile of each drug were compared. The data were analysed on the basis of intention to treat, using analysis of covariance comparing IOP in the three groups at 2 and 6 months, adjusting for baseline IOP. Tolerance levels were compared using Kruskal-Wallis test.. Of the 122 patients, 40 patients were given bimatoprost, 42 received latanoprost and 40 had travoprost. At 2 months, there was a significant difference between the three treatment groups (P = 0.013) with bimatoprost achieving a greater reduction in IOP than the other two drops. However, at 6 months, the difference was not statistically significant (P = 0.13). There was no significant difference in the tolerance profile.. All the three topical prostaglandin analogues are effective at lowering IOP, but bimatoprost was found to be most effective in the initial phase of the trial, and there was no statistically significant difference in the efficacy, among the three prostaglandin analogue eye drops after 6 months of treatment.

Topics: Adult; Aged; Aged, 80 and over; Amides; Bimatoprost; Cloprostenol; Female; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Travoprost

To assess the effects of combined therapy with latanoprost and beta blockers on optic nerve head (ONH) blood flow in normal-tension glaucoma (NTG) patients.. Intraocular pressure (IOP), ONH blood flow (laser speckle flowgraphy) and blood pressure were measured in 15 eyes of 15 NTG patients (41-76 years old) before treatment or after a 1-month washout period. Similar measurements were performed at 2 months after the commencement of treatment with latanoprost and at 3 months after the start of combined therapy of latanoprost with 0.5% timolol or 2% carteolol in a crossover study using the envelope method. Measurement was carried out 2-3 hr after the morning application of eyedrops.. Latanoprost decreased IOP with no significant change in ONH blood flow. Concomitant use of timolol or carteolol further decreased IOP with no significant difference between these two drugs. Only the combined therapy of latanoprost with carteolol significantly (p < 0.01) increased ONH blood flow by approximately 10%, compared to initial levels. There was no significant change in mean blood pressure, ocular perfusion pressure or pulse rate as a result of these therapies.. Topical latanoprost-carteolol combined therapy increased ONH blood flow in NTG patients, unlike latanoprost-timolol therapy. Because ocular perfusion pressure was unchanged, direct vasodilative effects were suspected as the mechanism.

Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Blood Flow Velocity; Blood Pressure; Carteolol; Ciliary Arteries; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Ophthalmic Artery; Ophthalmic Solutions; Optic Disk; Prostaglandins F, Synthetic; Regional Blood Flow; Retinal Artery; Timolol; Tonometry, Ocular

The most well-studied and widely prescribed fixed-combination drug for open-angle glaucoma is latanoprost/timolol. Its significant hypotensive effect is especially important in challenging cases, among which are patients with normal-tension glaucoma. With long life expectancy and the constant need for treatment, requirements are high for both the effectiveness of the drug and its tolerability. This paper presents a follow-up of 7 patients with normal-tension glaucoma who have been using the fixed combination of latanoprost/timolol for 10 years. All patients showed very good tolerability to the drug and their quality of life was preserved. A moderate rate of disease progression according to static perimetry was noted in one case. A mild degree of dry eye syndrome according to the OSDI questionnaire and an objective assessment of the state of the ocular surface was observed in one patient. The latanoprost/timolol fixed combination is a well-tolerated, highly effective and safe long-term treatment choice for normal-tension glaucoma.. Наиболее хорошо изученной и часто назначаемой при открытоугольной глаукоме является фиксированная комбинация латанопрост/тимолол. Ее значительный гипотензивный эффект особенно важен в тех случаях, когда снижение давления представляет собой сложную задачу. Именно к таким ситуациям относится лечение пациентов с глаукомой нормального давления. Большая ожидаемая продолжительность жизни и необходимость пожизненного лечения определяют высокие требования не только к эффективности терапии, но и к переносимости препарата. В данной работе приводится наблюдение за 7 пациентами с глаукомой нормального давления, применявшими фиксированную комбинацию латанопрост/тимолол в течение 10 лет. У всех пациентов отмечены очень хорошая переносимость комбинации и сохранение качества жизни. Умеренная скорость прогрессирования заболевания по данным статической периметрии отмечена в 1 случае. У 1 пациента по результатам опросника OSDI и объективной оценки состояния глазной поверхности была выявлена легкая степень синдрома сухого глаза. Таким образом, фиксированная комбинация латанопрост/тимолол является высокоэффективным и безопасным средством для долгосрочного лечения глаукомы нормального давления, обладающим хорошей переносимостью.

Topics: Antihypertensive Agents; Drug Combinations; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Ocular Hypertension; Prostaglandins F, Synthetic; Quality of Life; Timolol; Treatment Outcome

It is difficult to follow changes in the intraocular pressure (IOP) in glaucomatous eyes comprehensively because of the limited number of outpatient examinations. We report our findings in a case of normal tension glaucoma (NTG) in which frequent self-measurements of the IOP were used to evaluate the IOP-lowering effect of different medications.. A 50-year-old man with NTG had a nasal step visual field defect in his right eye and was being treated with 0.005% latanoprost (LAT) ophthalmic solution (XALATAN®).. The patient was diagnosed with NTG.. The patient had a mean IOP in the right eye of 10.9 ± 1.5 mm Hg (68 measurements in 1 month, Period A) during treatment with 0.005% LAT ophthalmic solution. During the second month (Period B), the mean IOP in the same eye was 9.8 ± 1.7 mm Hg (59 measurements) with treatment with a LAT and carteolol fixed combination (LCFC). And during the third month (Period C), the mean IOP was 7.4 ± 1.1 mm Hg (57 measurements) on the same right eye after the addition of brimonidine and brinzolamide fixed combination ophthalmic solution to the LCFC ophthalmic solution.. Comparisons of the IOPs between Periods A and B and between B and C showed that the reductions in the IOP were significant.. We conclude that frequent self-measurements of the IOP can determine that small changes of the IOPs are significant.

Topics: Antihypertensive Agents; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Ophthalmic Solutions; Prostaglandins F, Synthetic

To evaluate the long-term effect of latanoprost on central corneal thickness (CCT) in patients with normal-tension glaucoma (NTG).. This retrospective study included 41 eyes of 41 NTG patients and 40 eyes of 40 individuals with glaucoma suspect (controls). Newly diagnosed NTG patients with no previous glaucoma treatment were administered latanoprost 0.005% monotherapy once a day. CCTs were measured by ultrasound pachymetry before treatment and followed up annually for 5 years.. A significant reduction in mean CCT was observed in the NTG group [542.3±36.2 μm vs. 533.7±32.9 μm (n=41), P<0.001], but not in the control group [547.4±24.7 μm vs. 546.8±25.0 μm (n=40), P=0.59] at 5-year follow-up. In the NTG group, the CCT reduction mainly occurred during the first year of treatment (542.3±36.2 μm vs. 536.9±32.8 μm, P=0.001), and no significant correlation was found between CCT and intraocular pressure reductions (r=0.16, P=0.32).. Latanoprost significantly reduced CCT in NTG patients after 5 years of treatment. Serial observations of CCT might be helpful for the proper interpretation of glaucoma status in NTG patients.

Topics: Aged; Antihypertensive Agents; Cornea; Corneal Pachymetry; Female; Follow-Up Studies; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Retrospective Studies; Ultrasonography

To evaluate the effect of latanoprost on central corneal thickness (CCT) in patients with unilateral normal-tension glaucoma (NTG).. A total of 38 patients, with unilateral NTG, who were being treated in our glaucoma clinic and were receiving 0.005% latanoprost monotherapy over 24 months, were included in this study. The data were collected, retrospectively, with reviewing of the charts. The mean CCT and the CCT reduction from the baseline were assessed before the treatment, and at 3, 6, 9, 12, and 24 months after the initiation of the treatment. An unaffected eye was also evaluated for the control group. All the measurements were performed with a commercially available ultrasound pachymeter.. There were no significant differences between the eyes for the baseline intraocular pressure and CCT. The mean CCT trend decreased, except at 9 months after the treatment in the latanoprost group (affected eye), but only statistically significant after 24 months of treatment by using paired-sample t-test [544.6±38.4 vs. 540.3±37.8 μm (P=0.013)]. There was no statistically significant changes of CCT between the groups with repeated measures analysis of variance (P=0.635).. Topical therapy with latanoprost may decrease the CCT, over a period of 24 months, in patients with NTG. These data should be taken into consideration in a long-standing latanoprost treatment of NTG.

Topics: Administration, Ophthalmic; Adult; Aged; Antihypertensive Agents; Cornea; Corneal Pachymetry; Female; Follow-Up Studies; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Prostaglandins F, Synthetic; Retrospective Studies; Time Factors

To evaluate the efficacy of a monocular drug trial in eyes with normal-tension glaucoma (NTG).. This prospective study enrolled 74 patients with NTG. The monocular drug trial was started using latanoprost 0.005% for one week. If the intraocular pressure (IOP) reduction was greater than 15%, the same medication was administered to both eyes for one month. The unadjusted change and adjusted change (the change in the treated eye minus the change in the contralateral eye) in IOP were evaluated, and the predictors of IOP response were analyzed by multivariate linear regression.. Among the initial 74 patients, 31 (41.9%) were included; others were excluded because they did not meet the requisite conditions. The most significant predictors of IOP response in the initial eye and subsequent eye were the baseline IOPs in both eyes (β = 0.907, 0.771, respectively). The adjusted change in IOP of the initial eye had greater association (β = 0.589) with the IOP after monocular trial in the initial eye than that of unadjusted IOP change (β = 0.279). The adjusted change in IOP also had greater predictability (β = 0.348) for IOP after monocular trial in the subsequent eye than that of the unadjusted IOP change (β = 0.090).. Although the monocular trial in NTG patients had limited efficacy due to its stringent conditions, it was useful for evaluating the IOP response in the initial eye and for predicting the IOP response in the subsequent eye.

Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Female; Humans; Intraocular Pressure; Latanoprost; Linear Models; Low Tension Glaucoma; Male; Middle Aged; Prospective Studies; Prostaglandins F, Synthetic; Statistics, Nonparametric; Treatment Outcome

To investigate the progression rates of superior and inferior hemifield defects and each hemifield in bihemifield defects in normal-tension glaucoma patients and to compare the progression rates of each hemifield between groups in eyes with similar baseline hemifield defects.. Retrospective, observational cohort study.. Medical records of 142 normal-tension glaucoma patients who performed more than 5 reliable standard visual field tests with superior (group 2; n = 51), inferior (group 1; n = 44), or both hemifield (group 3; n = 47) defects were analyzed retrospectively. The changes in the mean thresholds of the 10 zones of the glaucoma hemifield test and the entire hemifield were inspected. A linear mixed effect model was used with age, gender, initial intraocular pressure, mean deviation, and pattern standard deviation controlled.. There were no significant differences in age and systemic and ocular factors between groups except for female gender, which showed a significant difference among the 3 groups (P = .032). The progression rate in group 2 was significantly faster than in group 1 (-0.713 dB/year vs -0.516 dB/year; P = .019), especially in central and nasal zones or than in the superior hemifield of group 3 (-0.717 dB/year vs -0.470 dB/year; P = .001). There was no significant difference in the progression rates between group 1 and the inferior hemifield in group 3 (-0.508 dB/year vs -0.441 dB/year; P = .312) or between the superior and inferior hemifields in group 3 (-0.468 dB/year vs -0.442 dB/year; P = .662).. More careful examination and caution is required in the treatment of normal-tension glaucoma patients with superior hemifield defect.

Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Cohort Studies; Disease Progression; Female; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Nerve Fibers; Prostaglandins F, Synthetic; Quinoxalines; Retinal Ganglion Cells; Retrospective Studies; Tonometry, Ocular; Vision Disorders; Visual Field Tests; Visual Fields

To evaluate the long-term effect of latanoprost on central corneal thickness (CCT) in patients with normal tension glaucoma (NTG).. This was a retrospective study and included 166 eyes of 166 patients [128 with NTG and 38 with glaucoma suspect, suspicious discs with normal visual fields, and an intraocular pressure (IOP) ≤21  mmHg as the control group]. Patients with newly diagnosed NTG and who had not had previous topical glaucomatous treatment were followed ≥24 months and received latanoprost 0.005% monotherapy once a day. CCT measurements were performed with an ultrasound pachymeter. CCT measurements before treatment and 24 months after treatment were analyzed.. There were no significant differences between the latanoprost group and the control group with respect to sex, age, baseline IOP, and CCT. A statistically significant reduction in the mean CCT was observed in the latanoprost group [535.5 ± 37.9 vs. 530.1 ± 36.4  μm (n = 128), P < 0.01], but not in the control group [543.1 ± 40.2 vs. 542.6 ± 37.0  μm (n = 38), P = 0.786].. Long-term use of latanoprost may decrease the CCT in patients with NTG. Therefore, clinicians must be aware of longitudinal CCT variations that may arise throughout the follow-up period for proper IOP targeting and management.

Topics: Administration, Topical; Adult; Aged; Antihypertensive Agents; Cornea; Drug Administration Schedule; Female; Humans; Intraocular Pressure; Latanoprost; Longitudinal Studies; Low Tension Glaucoma; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Retrospective Studies; Ultrasonography; Visual Fields

To investigate the effect of topical latanoprost on the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase 1 (TIMP-1) on the ocular surface.. Tears were collected from 39 patients with glaucoma who used latanoprost, 0.005%, eyedrops (Xalatan) and 28 healthy volunteers. The MMP-9 concentration was measured. Conjunctival epithelial cells were collected from 10 eyes of 10 patients before and 1 to 3 months after starting to take topical latanoprost, 0.005%, and MMP-1, MMP-9, and TIMP-1 messenger RNA (mRNA) expression was analyzed. Both eyes of 48 mice were treated once a day with latanoprost, 0.005%, timolol gel, 0.5%, eyedrops, vehicle of Xalatan, or phosphate-buffered saline, and MMP-9 and TIMP-1 mRNA expression was analyzed.. The median MMP-9 concentration in latanoprost-treated cases was 91.2 ng/mL (in controls, 19.7 ng/mL; P < .001). In latanoprost-treated cases, the relative ratio of MMP-9 to glyceraldehyde 3-phosphate dehydrogenase mRNA was significantly increased from 6.42 to 21.3 (P = .04, paired t test) and the relative amount of TIMP-1 was significantly decreased from 154 to 105 (P = .009). The relative amount of MMP-1 to GAPDH mRNA before and after latanoprost use was not significantly different (P = .16). In mice, MMP-9 expression was increased and TIMP-1 expression was decreased on the ocular surface at 8 weeks after latanoprost use.. The topical use of latanoprost increases MMP-1 and MMP-9 and decreases TIMP-1 on the ocular surface.. The use of topical latanoprost might not be recommended in patients with keratoconus or after laser-assisted in situ keratomileusis.

Topics: Administration, Topical; Animals; Antihypertensive Agents; Blotting, Western; Conjunctiva; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Female; Glaucoma, Open-Angle; Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); Humans; Immunohistochemistry; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Mice; Middle Aged; Prostaglandins F, Synthetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tears; Tissue Inhibitor of Metalloproteinase-1

We examined the effectiveness of latanoprost for reducing intraocular pressure (IOP) in Japanese patients with normal tension glaucoma (NTG) over a 5-year period.. Prospective interventional case series. The patients were classified into 2 groups based on mean IOP.. A total of 38 patients with NTG were studied after being classified into the high-tension (mean IOP 16 mmHg or greater, n = 27) and low-tension (mean IOP lower than 15 mmHg, n = 11) groups. IOP was measured and Humphrey Field Analyzer (HFA) examinations were conducted at 6, 12, 24, 36, 48, and 60 months after beginning a daily administration of latanoprost.. Mean IOP before administration was 17.6 mmHg in the high-tension group, which was reduced to 13.9, 14.6, 14.4, 14.1, 13.6, and 14.6 mmHg at 6, 12, 24, 36, 48, and 60 months, respectively, after beginning administration. That in the low-tension group was 13.6 mmHg before administration, and then was reduced to 12.2, 11.4, 11.5, 12.5, 10.5, and 11.5 mmHg, respectively, after beginning administration was noted. Mean deviation (MD) values in the HFA examinations were reduced by -4.27 and -1.49 dB after 5 years in the high- and low-tension groups, respectively.. Latanoprost administration was effective in reducing IOP over a 5-year period in a range of 3.1-4.1 and 1.3-3.6 mmHg in NTG patients with high- and low-tension levels, respectively. In addition, our results indicate that latanoprost helped to prevent a decrease in MD values in both groups, as shown by the results of HFA examinations.

Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Female; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Prostaglandins F, Synthetic; Visual Fields